Azilsartan alone and in combination for the treatment of hypertension – clinical utility and patient considerations

Jocelyn D Jones¹
Sylvia H Jackson¹
Charlie Colquitt²

¹College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Jacksonville, FL, USA; ²College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tampa, FL, USA

Abstract: Hypertension is a common disease that leads to significant cardiovascular morbidity and mortality. Adequate blood pressure control is essential in preventing end organ complications. One of the most popular antihypertensive strategies for the treatment of elevated blood pressure is to attenuate the actions of the renin-angiotensin-aldosterone system. The agents include the angiotensin converting enzyme inhibitors, angiotensin II receptor blockers (ARBs), direct renin inhibitors, and aldosterone antagonists. The ARBs inhibit the action of angiotensin II by binding to the angiotensin II type 1 receptor. The inhibition of angiotensin II results in a dose dependent decrease in peripheral resistance, reduction in vascular smooth muscle contraction, and reduced synthesis of aldosterone in the kidneys. Azilsartan medoxomil is a highly selective ARB. It was approved by the US Food and Drug Administration in February 2011 for the treatment of hypertension in adults. It is the eighth ARB to be added to the market. This article will discuss the pharmacologic and clinical characteristics of azilsartan medoxomil to help differentiate it from other ARBs that are used for the management of hypertension.

Keywords: hypertension, azilsartan medoxomil, angiotensin II receptor blocker, ARB

Introduction to current treatments for hypertension

In the US, about 77.9 million people (31%) aged 20 years and older have high blood pressure. Data from the 2007 to 2010 National Health and Nutrition Examination Survey report demonstrates that one in three adults have high blood pressure.¹ This has not changed significantly from 1999 to 2002 (28.1%). However, the prevalence of pharmacologic treatment among those with hypertension increased from 60.3% to 74.9%. Fortunately, the prevalence of control has also increased from 33.2% in 1999 to 2002 to 52.5% in 2007 to 2010.¹ Even with this progress, high blood pressure was listed as a primary or contributing cause of death in about 348,102 of the more than 2.4 million US deaths in 2009.¹ Forty six thousand deaths could be averted each year if all hypertensive patients were treated effectively.² The American Heart Association has estimated the direct and indirect cost of high blood pressure in 2009 to be $51.0 billion.¹

Currently, there are eight classes of medications used for the treatment of hypertension. They include diuretics, alpha adrenergic blockers, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta adrenergic blockers, calcium channel blockers (CCBs), central alpha adrenergic receptor agonists, and direct renin inhibitors. Some patients have an indication for a specific drug or drugs (eg, a nondihydropyridine CCB or beta blocker for rate control in patients with...
atrial fibrillation). In the absence of a specific indication, four of these classes have been used for initial monotherapy: thiazide diuretics, long acting CCBs (most often a dihydropyridine), and ACE inhibitors or ARBs.

There are currently eight ARBs approved in the US: azilsartan (AZL) (Edarbi), candesartan (Atacand), eprosartan (Teveten), irbesartan (Avapro), losartan (Cozaar), olmesartan (Benicar), telmisartan (Micardis), and valsartan (Diovan). Traditionally, ARBs have been used to treat patients who are intolerant to ACE inhibitors due to cough. AZL is the newest addition to the ARB class. It was approved in February 2011, and is the only ARB combined with the diuretic, chlorthalidone (CLD) Edarbyclor.

**Review of pharmacology and mode of action**

The renin-angiotensin-aldosterone system (RAAS) is one therapeutic pathway that is targeted by the ACE inhibitors and ARBs to reduce hypertension. Renin, which is primarily released by the kidneys, stimulates the formation of angiotensin I in blood and tissues. Angiotensin II is formed from the cleavage of angiotensin I with the assistance of ACE. The inhibition of ACE is the rate limiting step that reduces water and sodium retention due to aldosterone release. Azilsartan selectively blocks the binding of angiotensin II to the angiotensin II subtype-1 (AT\(_1\)) receptor which is found in many tissues, including vascular smooth muscle and adrenal glands.\(^3\) Therefore, the actions of azilsartan go beyond the RAAS in the reduction of hypertension.

Azilsartan has a 10,000 fold greater affinity for the AT\(_1\) receptor than the angiotensin II subtype-2 (AT\(_2\)) receptor. By binding to the AT\(_1\) receptor, azilsartan prevents the actions of vasoconstriction, increases sodium retention, suppresses renin secretion, increases endothelin secretion, and increases vasopressin release. Although AT\(_2\) receptors are found in the fetus, numbers are greatly reduced in adults.\(^5\) These receptors are found in the brain, heart, and adrenal gland, but the effects of the receptors have not been found to be associated with cardiovascular homeostasis.\(^3,5\)

The structure of azilsartan is a modification of the tetrazole ring found in candesartan and other ARBs. The tetrazole ring is replaced with a 5 member oxo-oxadiazole ring, which allows azilsartan to be less acidic and more lipophilic than candesartan.\(^6\) Azilsartan medoxomil (AZL-M) is a prodrug derived from the chemical formula azilsartan kamedoxomil, the potassium salt formulation. It is rapidly hydrolyzed to the active metabolite, azilsartan, during the gastrointestinal absorption phase.\(^3\)

**Pharmacokinetics**

The oral bioavailability of azilsartan is approximately 60% and it is not affected by the presence of food.\(^3\) Azilsartan is almost completely bound to plasma proteins (>99%), mainly by serum albumin. Peak plasma concentrations are achieved within 1.5–3 hours.\(^3\) Steady state levels are achieved in 5 days. Azilsartan is metabolized mostly via cytochrome P450, family 2, subfamily C, polypeptide 9 (CYP2C9) into two inactive metabolites. The main metabolite,\(\text{M-II}\), is formed by O-dealkylation; and the minor metabolite, referred to as M-I, is formed by decarboxylation. The elimination half-life is 11 hours.\(^3\) Elimination of the drug is via feces (55%) and urine (42%). About 15% of the dose is eliminated as unchanged azilsartan in urine. Renal clearance is 2.3 mL/min. In rats, azilsartan crosses the blood–brain barrier and placental barrier.\(^3\)

**Efficacy studies**

The US Food and Drug Administration’s (FDA) approval of AZL-M was based on seven double blind, randomized studies.\(^7-10,11,13\) Of the seven studies, five were placebo controlled and four used an active comparator as a control agent. Approximately 7,000 hypertensive patients participated in the studies. The study time frames ranged from 6 weeks to 6 months in duration. The clinical trials of AZL-M are summarized in Table 1 and are discussed next.

**Bakris et al**

Bakris et al\(^7\) randomized 1,275 patients with primary hypertension to receive AZL-M, olmesartan medoxomil (OLM-M), or placebo for 6 weeks. This randomized, double blind, placebo controlled, multicenter study assessed the change in baseline mean 24 hour ambulatory systolic blood pressure (SBP) from baseline. Prior to randomization, patients received placebo for a 2 week run-in period. In addition, patients who previously received antihypertensive treatment had a 3 to 4 week washout period. Men and women aged 18 years and older with primary hypertension and baseline 24 hour mean ambulatory systolic pressure ≥130 mmHg and ≤170 mmHg were studied; 142 patients received placebo and the remainder received 20 mg, 40 mg, or 80 mg AZL-M, or 40 mg OLM-M. The mean age of participants was 58 ± 11 years and the baseline mean 24 hour SBP was 146 mmHg.

Each dose of AZL-M and OLM-M significantly reduced 24 hour SBP when compared to placebo (\(P < 0.001\) for all doses). When compared with OLM-M 40 mg, AZL-M 40 mg was noninferior and AZL-M 80 mg produced significant
reductions in 24 hour mean SBP ($P = 0.038$). AZL-M is more efficacious at its maximal dose than the maximal dose of OLM-M.

**White et al**

This randomized, double blind, multicenter, placebo and active controlled trial studied the antihypertensive effects of the two available dosages of AZL-M (40 mg and 80 mg), in comparison with valsartan (VAL) 320 mg and OLM-M 40 mg.

The participants in this study included men and women 18 years and older whose clinic SBP ranged between 150 mmHg and 180 mmHg, and whose 24 hour mean SBP ranged between 130 mmHg and 180 mmHg. The participants underwent a 3 to 4 week washout of any previous therapy concurrent with a 2 week, single blind, placebo administration period. All participants were then randomly assigned to receive daily doses of AZL-M 20 mg, AZL-M 40 mg, VAL 160 mg, OLM-M 20 mg, or placebo. Two weeks later, the doses of the agents were doubled in each respective group and were continued for 4 more weeks. A total of 1,291 patients were randomized to the study groups. The mean age of the participants was 56 years, 54% were men, and baseline

### Table 1 Azilsartan medoxomil clinical trials

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Subjects (N)</th>
<th>Dosage</th>
<th>Duration</th>
<th>Primary outcome</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bakris et al</td>
<td>R, DB, PC, parallel</td>
<td>1,275</td>
<td>AZL-M 20, 40, 80 mg once daily versus OLM-M 40 mg once daily versus placebo</td>
<td>6 weeks</td>
<td>Change in 24 hour SBP by ABPM from baseline</td>
<td>AZL-M 80 mg (–14.6 mmHg) significantly improved mean SBP versus OLM-M, olmesartan medoxomil (–12.6 mmHg) ($P = 0.038$); 40 mg (–13.5 mmHg) was noninferior to placebos; <strong>AZL-M 80 mg</strong> (–14.5 ± 0.7 mmHg) significantly improved mean SBP more than OLM-M, olmesartan medoxomil (11.7 ± 0.7 mmHg) and VAL (–10.2 ± 0.7 mmHg)</td>
</tr>
<tr>
<td>White et al</td>
<td>R, DB, PC</td>
<td>1,291</td>
<td>AZL-M 40, 80 mg once daily versus VAL 320 mg once daily versus OLM-M 40 mg once daily versus placebo</td>
<td>6 weeks</td>
<td>Change in 24 hour mean SBP from baseline</td>
<td><strong>AZL-M 40 mg</strong> (–14.9 mmHg) and 80 mg (–15.3 mmHg) significantly improved 24 hour mean SBP more than VAL (–11.3 mmHg); <strong>AZL-M 40 mg</strong> (–20.6 ± 0.9 mmHg) and 80 mg (–21.2 ± 0.9 mmHg) significantly improved mean clinic SBP more than RAM (–12.2 ± 0.9 mmHg); <strong>P &lt; 0.001 for both</strong></td>
</tr>
<tr>
<td>Sica et al</td>
<td>R, DB, PC, parallel</td>
<td>984</td>
<td>AZL-M 40, 80 mg once daily versus VAL 320 mg once daily</td>
<td>24 weeks</td>
<td>Change in 24 hour mean SBP by ABPM from baseline</td>
<td><strong>AZL-M 40 mg</strong> and 80 mg + AML 5 mg significantly reduced mean SBP versus AML + placebo; <strong>P &lt; 0.001 for both</strong></td>
</tr>
<tr>
<td>Bönner et al</td>
<td>R, DB, parallel</td>
<td>884</td>
<td>AZL-M 40, 80 mg once daily versus RAM 10 mg once daily</td>
<td>24 weeks</td>
<td>Change in sitting clinic SBP from baseline</td>
<td><strong>AZL-M 40 mg</strong> + CLD (–31.7 mmHg) and 80 mg + CLD (–31.3 mmHg) significantly improved mean SBP more than placebo + CLD (–15.9 mmHg); <strong>P &lt; 0.001 for both</strong></td>
</tr>
<tr>
<td>Weber et al</td>
<td>R, DB, PC</td>
<td>562</td>
<td>AZL-M 40, 80 mg once daily + AML 5 mg once daily versus AML 5 mg once daily + placebo</td>
<td>6 weeks</td>
<td>Change in 24 hour mean SBP by ABPM from baseline</td>
<td><strong>AZL-M 40 mg</strong> + CLD reduced clinic SBP (–35.1 mmHg) significantly more than <strong>AZL-M + HCTZ</strong> (–29.5 mmHg); <strong>P &lt; 0.001 for both</strong></td>
</tr>
<tr>
<td>Sica et al</td>
<td>R, DB, PC, parallel</td>
<td>448</td>
<td>AZL-M 40, 80 mg once daily + CLD 25 mg once daily versus placebo + CLD 25 mg once daily</td>
<td>6 weeks</td>
<td>Change in 24 hour mean SBP by ABPM from baseline</td>
<td></td>
</tr>
<tr>
<td>Bakris et al</td>
<td>R, DB</td>
<td>609</td>
<td>AZL-M 40 mg once daily + CLD 12 mg once daily versus AZL-M 40 mg once daily + HCTZ 12.5 mg once daily</td>
<td>10 weeks</td>
<td>Change in clinic SBP from baseline</td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** ABPM, ambulatory blood pressure monitoring; AML, amlodipine; AZL-M, azilsartan medoxomil; CLD, chlorthalidone; DB, double blind; HCTZ, hydrochlorothiazide; OLM-M, olmesartan medoxomil; PC, placebo controlled; R, randomized; RAM, ramipril; SBP, systolic blood pressure; VAL, valsartan.
24 hour mean SBP was 145 mmHg. The primary efficacy end point was the change from baseline in the 24 hour mean SBP after 6 weeks of treatment.

The data collected from 1,088 study participants was tested for noninferiority and superiority of the two different doses of AZL-M compared with VAL and OLM-M. AZL-M 80 mg lowered mean SBP (−14.3 mmHg), VAL 320 mg (−10 mmHg; $P < 0.001$), and OLM-M 40 mg (−11.7 mmHg; $P = 0.009$). The data demonstrated that AZL-M at a dose of 80 mg is superior in efficacy to both maximal doses of VAL and OLM-M. AZL-M 40 mg was noninferior to OLM-M 40 mg.

**Sica et al**

A 24-week, randomized, double blind, placebo controlled study was conducted to compare the antihypertensive efficacy of AZL-M with that of maximum dose VAL. Men and women aged 18 years or older with hypertension were included if their clinic SBP was ≥150 mmHg and ≤180 mmHg and if their 24 hour mean SBP was ≥130 mmHg and ≤170 mmHg. Sica et al randomized 984 patients to receive AZL-M 40 mg or 80 mg, or VAL 320 mg in a 1:1:1 ratio. For the first 2 weeks, the participants received lower initial doses of the study drugs (ie, AZL-M 20 mg and VAL 80 mg). The doses were forced titrated after 2 weeks. The mean age of participants was 58 years, 52% were men, and the mean baseline 24 hour SBP was 145.6 mmHg. The primary end point was change from baseline in 24 hour mean ambulatory SBP following 24 weeks of treatment. Changes from baseline in 24 hour mean SBP were significantly greater with AZL-M 40 mg and 80 mg than with VAL 320 mg ($P < 0.001$).

**Bönner et al**

This randomized, double blind study compared the antihypertensive efficacy and the safety of AZL-M with ramipril (RAM). Participants with clinic SBP ranging between 150 mmHg and 180 mmHg were included in the study. The participants were randomly assigned to receive daily doses of AZL-M 20 mg, AZL-M 40 mg, or RAM 10 mg. For the first 2 weeks of the study the patients received lower doses of the study agents (AZL-M 20 mg, and RAM 2.5 mg). The doses were maximized in each study group for the remainder of the 24 week study.

A total of 884 men and women participated in the randomization. The mean age was 57 years, 52.4% were men, and the baseline SBP was approximately 160 mmHg. The primary efficacy end point was change in sitting clinic blood pressure from baseline. Safety parameters and adverse events (AEs) were also studied. AZL-M 40 mg and 80 mg reduced SBP significantly more than RAM ($P < 0.001$). Table 2 illustrates the conclusion that long-term treatment with AZL-M was more effective in reducing SBP when compared to RAM 10 mg. Additionally, AEs leading to discontinuation of treatment and occurrence of cough were less frequent with AZL-M 40 mg and 80 mg than with RAM 10 mg (1.0% and 1.4%, versus 8.2%).

### Rationale of combination therapy with other antihypertensives

With the worldwide prevalence of hypertension affecting approximately 40% of adults aged 25 years and above, the need for dual therapy may be necessary for adequate blood pressure control. AZL-M can be combined with other classes of antihypertensive agents to achieve adequate blood pressure control. However, it is not recommended to be coadministered with aliskiren in patients with diabetes. In addition, AZL-M with aliskiren should be avoided in patients with renal impairment of glomerular filtration rate <60 mL/min.

The results from Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial demonstrated that CLD based therapy was superior to lisinopril, amlopidine (AML), and doxazosin in preventing one or more forms of cardiovascular disease. The British National Institute of Clinical Excellence (NICE) guidelines prefers the use of CLD or indapamide if the use of a diuretic is warranted. CLD is a thiazide-like diuretic that is pharmacokinetically and pharmacodynamically different from hydrochlorothiazide (HCTZ). CLD and its metabolites have a longer half-life than hydrochlorothiazide and its metabolites. The half-life of CLD is approximately 42 hours and that of HCTZ is 6.5–9 hours. Additionally, available studies suggest that

### Table 2 Change in clinic systolic blood pressure

<table>
<thead>
<tr>
<th></th>
<th>Azilsartan 40 mg</th>
<th>Azilsartan 80 mg</th>
<th>Ramipril 10 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Baseline</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SBP mean (mmHg)</td>
<td>160.9 ± 0.5</td>
<td>161.5 ± 0.5</td>
<td>161.4 ± 0.5</td>
</tr>
<tr>
<td>Δ week 24 SBP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(mmHg)</td>
<td>−20.6 ± 0.9</td>
<td>−21.2 ± 0.9</td>
<td>−12.2 ± 0.9</td>
</tr>
<tr>
<td>Δ versus ramipril</td>
<td>−8.4</td>
<td>−9.0</td>
<td></td>
</tr>
<tr>
<td>(mmHg) (95% CI)</td>
<td>(−11.0, −5.8)</td>
<td>(−11.7, −6.4)</td>
<td></td>
</tr>
<tr>
<td>$P &lt; 0.001$</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


**Abbreviations:** CI, confidence interval; SBP, systolic blood pressure.
50 mg HCTZ is approximately equivalent to 25 mg to 37 mg CLD. The potency and extended duration of action of CLD is more likely to maintain net negative sodium balance and substantially add to the blood pressure lowering effect of the RAAS inhibitor. The manufacturer of AZL-M recognized the benefits of CLD, and the combination of AZL-M and CLD was approved in the US in December 2011.

The combination of a CCB and an ARB is a rational approach. The benefits of CCB/ARB combination therapy include additive blood pressure lowering effects and lower incidences of AEs. The efficacy of this combination has been investigated in clinical trials utilizing AML combined with OLM-M, telmisartan, or VAL. Currently, there are three FDA approved combinations of an ARB and a CCB: OLM-M and AML (Azor), VAL and AML (Exforge), and telmisartan and AML (Twynsta).

Weber et al

In this double blind placebo controlled trial, patients with stage 2 hypertension were randomized into one of three study groups. AML 5 mg was used in combination with AZL-M 40 mg, AZL-M 80 mg, or placebo for 6 weeks. A total of 562 patients with stage 2 hypertension were evaluated in this study. The mean age of the participants was 58 years and 51% were men. The primary end point was change in 24 hour mean SBP as determined by ambulatory blood pressure monitoring. Clinic systolic and diastolic blood pressures, response rates, and AEs were secondary end points.

Table 3 illustrates that both AZL-M-AML combinations significantly lowered blood pressure when compared to the placebo-AML combination ($P < 0.001$). Response rates were 43%, 66%, and 69% for the AML combinations with placebo, AZL-M 40 mg, or AZL-M 80 mg, respectively. Peripheral edema occurred more frequently with the placebo combination than with the AZL-M combination (4.9% versus 2.1%).

This study demonstrated that combining AML 5 mg with AZL-M can be very efficacious in the treatment of patients with stage 2 hypertension. It can also be suggested that AZL-M was instrumental in decreasing the occurrence rate of peripheral edema, a common AE with the use of AML.

Sica et al

Sica et al used this 6-week randomized, double blind, placebo controlled trial to evaluate the efficacy of AZL-M combined with CLD for the treatment of stage 2 hypertension. Individuals were included in the study if they had a clinic SBP between 160 mmHg and 190 mmHg, and a 24 hour mean SBP between 140 mmHg and 180 mmHg. A total of 448 patients with similar 24 hour mean SBP measurements were randomized into one of three study groups. CLD 25 mg was added to AZL-M 40 mg, AZL-M 80 mg, or placebo. The primary end point was change from baseline in 24 hour mean SBP as determined by ambulatory blood pressure monitoring.

Absolute reductions in 24 hour mean SBP were considerably higher in the study groups where CLD was added to AZL-M 40 mg or 80 mg (−31.7 mmHg and −31.3 mmHg, respectively) than in the study group combining CLD with placebo (−15.9 mmHg; $P < 0.001$). The addition of CLD to either available strength of AZL-M significantly decreased both clinic SBP and 24 hour mean SBP in stage 2 hypertensive patients.

Bakris et al

The first double blind study to compare the effects of the two thiazide diuretics in combination with an ARB utilized AZL-M. Bakris et al conducted a 10-week, double blind multicenter study that included more than 600 patients with moderate to severe hypertension. All patients received a daily dose of AZL-M 40 mg for the first 2 weeks of the trial. For the following 4 weeks, the patients were randomized to either receive a fixed dose combination of AZL-M 40 mg and CLD 12.5 mg, or AZL-M 40 mg coadministered with hydrochlorothiazide 12.5 mg. During weeks 7 through 10, the diuretics were titrated to 25 mg for the patients who did not reach target blood pressure. The primary end point was change in clinic SBP from baseline.
Six weeks after the beginning of the study, the reduction in clinic SBP was higher in the CLD combination group than in the HCTZ group (−35.1 mmHg versus −29.5 mmHg). The majority of patients in the CLD group achieved the target clinic blood pressure in comparison to the HCTZ group (64.1% versus 45.9%; P < 0.001). The mean difference in 24 hour ambulatory SBP at week 6 was −5.8 mmHg in favor of the AZL-M and CLD group. Fifteen percent more patients in the HCTZ study group required the increase in diuretic dose than in the CLD group. The fixed combination of AZL-M and CLD significantly decreased clinic blood pressure measurements and 24 hour mean SBP more than AZL-M with HCTZ.

The two additional studies that will be discussed were published after the approval of AZL-M.

Sica et al

This 8-week randomized, double blind factorial study compared the efficacy and safety of fixed dose combinations of AZL-M and CLD with the individual monotherapies. A total of 1,714 participants were randomized to AZL-M 0 mg, 20 mg, 40 mg, or 80 mg and/or CLD 0 mg, 12.5 mg, or 25 mg. The study participants were men and women 18 years of age and older with a SBP ranging from 160 mmHg to 190 mmHg. The mean age was 57 years, 47% were men, and 20% were black. The primary end point was the change in trough SBP by ambulatory blood pressure monitoring at week 8.

Each AZL-M/CLD fixed dose combination reduced the trough SBP significantly more than CLD or AZL-M alone (P < 0.001). In patients with stage 2 hypertension, treatment with a AZL-M and CLD fixed dose combination resulted in greater SBP reduction when compared to either agent alone.

Cushman et al

In this large, forced titration active comparator study, AZL-M plus CLD was compared to OLM-M plus HCTZ. This study evaluated the antihypertensive efficacy, safety, and tolerability of the two combinations. The design was a randomized, three arm, double blind, 12 week study of 1,071 participants. The three arms were AZL-M/CLD 20 mg/12.5 mg forced titrated to 40 mg/25 mg, AZL-M/CLD 40 mg/12.5 mg forced titrated to 80 mg/25 mg, and OLM-M/HCTZ 20 mg/12.5 mg forced titrated to 40 mg/25 mg. The force titration occurred at weeks 4 and 8. The mean age was 57 years, 59% were men, 73% were white, and 22% were black. Baseline clinic blood pressure was 165/96 mmHg. The primary end point was a change from baseline in trough, seated, and clinic SBP at week 12.

The changes in clinic SBP at week 12 were significantly greater in the AZL-M/CLD arms than in the OLM-M/HCTZ arm (−42.5 ± 0.8, −44.0 ± 0.8, and −37.1 ± 0.8 mmHg; P < 0.001). This study has demonstrated that ALZ-M/CLD fixed dose combinations have superior antihypertensive efficacy when compared to the maximum approved dose of OLM-M/HCTZ.

Safety and tolerability

The safety of AZL-M (doses of 20, 40, or 80 mg) has been evaluated in 4,814 patients in clinical trials with durations up to 1 year. AZL-M was well tolerated with an overall incidence of adverse reactions similar to placebo. Diarrhea was reported in up to 2% of patients on AZL-M 80 mg versus 0.5% of those on placebo. Other side effects including nausea, asthenia, fatigue, muscle spasm, dizziness, and cough were reported with an incidence of ≥0.3% versus placebo in more than 3,300 patients. Small increases in serum creatinine were observed in patients on AZL-M 80 mg. Patients >75 years of age or those patients with moderate or severe renal impairment are more likely to report serum creatinine increases. Low hemoglobin (0.2%), hematocrit (0.4%), and red blood cell counts (0.3%) were observed in AZL-M treated patients versus placebo (0%).

During the second and third trimester of pregnancy, agents that affect the RAAS reduce fetal renal function and increase fetal morbidity and mortality. In addition to other ARBs and ACE inhibitors, AZL-M is not recommended during pregnancy and is pregnancy category D. AZL-M was excreted at low concentrations in the milk of lactating rats. The excretion possibility for human milk is currently unknown.

No safety and efficacy data is available in patients under 18 years of age. No dose adjustment is necessary for elderly patients, for patients with renal impairment, or in patients with mild to moderate hepatic impairment. It should be noted that AZL-M has not been studied in patients with severe hepatic impairment.

AZL-M is metabolized by CYP2C9. Therefore, caution should be advised when AZL-M is administered with strong modulators of this enzyme. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors may attenuate the antihypertensive effects of ARBs. Concurrent use may cause worsening of renal function in patients who are elderly, volume depleted, or who have baseline compromised renal function.
function. AZL-M does not appear to have any clinically significant drug interactions with AML, antacids, CLD, digoxin, fluconazole, glyburide, ketoconazole, metformin, pioglitazone, and warfarin.

**Patient focused perspectives such as quality of life, patient satisfaction/acceptability, adherence, and uptake**

A patient’s quality of life, satisfaction, and adherence regarding medications are vital components to consider when selecting a medication regimen. Poor adherence to medical treatment is a well-recognized problem in the literature. In the US, nonadherence to medications causes 125,000 deaths annually and accounts for 10% to 25% of hospital and nursing home admissions. Therefore, nonadherence to medications is one of the most expensive disease categories.

The complexity of a treatment regimen can affect adherence. Strategies used to simplify a regimen have already become standardized practices. Adherence improves remarkably when a patient is prescribed a pill that can be taken once a day. This can be accomplished with a longer acting drug or with a pill that combines more than one drug.

Medication side effects are highly prevalent and significantly associated with medication nonadherence. Nonadherence is significantly associated with increased health care resource use. Prevention, identification, and effective management of medication induced side effects are important to maximize adherence and reduce health resource use.

AZL-M has the potential to help decrease patient nonadherence due to pill burden and side effects. The pharmacodynamic profile of AZL-M allows for once a day dosing, which may increase patients’ medication adherence. The combination of AZL-M and CLD (Edarbyclor) provides substantial blood pressure lowering which can potentially obviate the need for the addition of other agents. Another advantage of AZL-M is that it should not affect bradykinin levels, thereby reducing the incidence of cough which is often observed with ACE inhibitors. In addition, the study conducted by Weber et al demonstrated that when AZL-M is combined with AML, the peripheral edema was reduced in comparison to AML alone (2.1% versus 4.9%).

Currently, there are three ARBs that are available as generic products. They include irbesartan, losartan, and eprosartan. The average wholesale price for a 30-day supply of the maximum dose of each ARB is: $92 for irbesartan, $92 for losartan, $103 for eprosartan, $107 AZL-M, $161 for telmisartan, $167 for OLM-M, $183 for VAL, and $105 for candesartan. It appears that the generic products are less expensive, however, the brand name ARB, AZL-M, may be pharmacoeconomical for most patients based on the price of the other brand name ARBs.

**Conclusion**

Hypertension is a risk factor for cardiovascular disease and having a strict or controlled blood pressure is critical in reducing or preventing cardiovascular disease. Globally, cardiovascular disease accounts for approximately 17 million deaths a year, nearly one third of the total number of deaths. Of these, complications of hypertension account for 9.4 million deaths worldwide every year.

The NICE guidelines recommend an ARB as a first line option in patients younger than 55 years of age. The seventh Report of the Joint National Committee and European guidelines recommend ARBs as preferred alternatives to ACE inhibitors for patients with various comorbidities or cardiovascular risk factors.

AZL-M is the latest ARB approved for the treatment of hypertension. When compared to other ARBs (OLM-M and VAL) and an ACE inhibitor (RAM), AZL-M proved to be more effective at reducing blood pressure. The greater blood pressure reduction observed may be related to the pharmacologic profile, including slowed AT1 receptor dissociation and improved receptor specificity. The combination of AZL-M and CLD has proven to significantly lower blood pressure more than AZL-M and HCTZ. Therefore, if a diuretic is needed for additional blood pressure reduction, CLD is the more appropriate option to add to AZL-M.

AZL-M is available in 40 mg and 80 mg tablets. The recommended initial dose is 80 mg daily. Prescribers should consider 40 mg daily for patients with volume depletion or who are on high dose diuretics. Currently, AZL-M should be considered as an alternative for stage 1 and 2 hypertension or as an adjunctive therapy when preferred agents fail to control blood pressure.

**Disclosure**

The authors report no conflict of interest in this work.

**References**


